Elderly heart failure (HF) patients are underrepresented in clinical trials, though are a large proportion of patients in real-world practice. We investigated practice-based, secondary care HF management in a large group of chronic HF patients aged ≥ 80 years (octogenarians).
We analyzed electronic health records of 3490 octogenarians with chronic HF at 34 Dutch outpatient clinics in the period between 2013 and 2016 , 49% women. Study patients were divided into HFpEF [LVEF ≥ 50%; n = 911 (26.1%)], HFrEF [LVEF < 40%; n = 2009 (57.6%)] and HF with mid-range EF [HFmrEF: LVEF 40–49%; n = 570 (16.3%)].
Most HFrEF patients aged ≥ 80 years received a beta blocker and a renin–angiotensin system (RAS) inhibitor (angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker), i.e. 78.3% and 72.8% respectively, and a mineralocorticoid receptor antagonist (MRA) was prescribed in 52.0% of patients. All three of these guideline-recommended medications (triple therapy) were given in only 29.9% of octogenarians with HFrEF, and at least 50% of target doses of triple therapy, beta blockers, RAS inhibitor and MRA, were prescribed in 43.8%, 62.2% and 53.5% of the total group of HFrEF patients. Contraindications or intolerance for beta blockers was present in 3.5% of the patients, for RAS inhibitors and MRAs in, 7.2% and 6.1%
The majority of octogenarians with HFrEF received one or more guideline-recommended HF medications. However, triple therapy or target doses of the medications were prescribed in a minority. Comorbidities and reported contraindications and tolerances did not fully explain underuse of recommended HF therapies.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Metra M, Teerlink JR (2017) Heart failure. Lancet 390(10106):1981–1995
van Deursen VM, Urso R, Laroche C, Damman K, Dahlström U, Tavazzi L et al (2014) Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 16(1):103–111
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP et al (2017) Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19(12):1574–1585
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787–1847
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891–975
Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS (2017) Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 19(11):1414–1423
Thomas S, Rich MW (2007) Epidemiology, pathophysiology, and prognosis of heart failure in the elderly. Clin Geriatr Med 23(1):1–10
Flather MD, Shibata MC, Coats AJ, van Veldhuisen DJ, Parkhomenko A, Borbola J et al (2005) Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26(3):215–225
Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J et al (2013) EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 15(7):808–817
Van Spall HG, Toren A, Kiss A, Fowler RA (2007) Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297(11):1233–1240
Komajda M, Hanon O, Hochadel M, Follath F, Swedberg K, Gitt A et al (2007) Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. Eur Heart J 28(11):1310–1318
Komajda M, Hanon O, Hochadel M, Lopez-Sendon JL, Follath F, Ponikowski P et al (2009) Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J 30(4):478–486
Moubarak G, Ernande L, Godin M, Cazeau S, Vicaut E, Hanon O et al (2013) Impact of comorbidity on medication use in elderly patients with cardiovascular diseases: the OCTOCARDIO study. Eur J Prev Cardiol 20(4):524–530
Vorilhon C, Chenaf C, Mulliez A, Pereira B, Clerfond G, Authier N et al (2015) Heart failure prognosis and management in over-80-year-old patients: data from a French national observational retrospective cohort. Eur J Clin Pharmacol 71(2):251–260
Mizuno M, Kajimoto K, Sato N, Yumino D, Minami Y, Murai K et al (2016) Clinical profile, management, and mortality in very-elderly patients hospitalized with acute decompensated heart failure: an analysis from the ATTEND registry. Eur J Intern Med 27(1):80–85
Savarese G, Dahlström U, Vasko P, Pitt B, Lund LH (2018) Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study. Eur Heart J 39(48):4257–4265
Stolfo D, Uijl A, Benson L, Schrage B, Fudim M, Asselbergs FW et al. (2019) Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry. Eur J Heart Fail Sep. https://doi.org/10.1002/ejhf.1615
Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI et al (2018) Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry. J Am Coll Cardiol 72(4):351–366
Brugts JJ, Linssen GCM, Hoes AW, Brunner-La Rocca HP, Investigators of CHECK-HF (2018) Real-world heart failure management in 10,910 patients with chronic heart failure in the Netherlands: design and rationale of the Chronic Heart failure ESC guideline-based Cardiology practice Quality project (CHECK-HF) registry. Neth Heart J 26(5):272–279
Brunner-La Rocca HP, Linssen GC, Smeele FJ, van Drimmelen AA, Schaafsma HJ, Westendorp PH et al (2019) Contemporary drug treatment of chronic heart failure with reduced ejection fraction. The CHECK-HF registry. J Am Coll Cardiol HF 7(1):13–21
National Cardiac Audit Programme (2018) National Heart Failure Audit 2016/17 Summary Report. https://www.nicor.org.uk/wp-content/uploads/2018/11/Heart-Failure-Summary-Report-2016-17.pdf
Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V et al (2019) Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet 394(10205):1254–1263
Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlström U et al (2018) Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 20(9):1326–1334
Forman DE, Cannon CP, Hernandez AF, Liang L, Yancy C, Fonarow GC (2009) Influence of age on the management of heart failure: findings from Get With the Guidelines-Heart Failure (GWTG-HF). Am Heart J 157(6):1010–1017
Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P et al (2009) BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301(4):383–392
Brunner-La Rocca HP, Eurlings L, Richards AM, Januzzi JL, Pfisterer ME, Dahlström U et al (2015) Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. Eur J Heart Fail 17(12):1252–1261
Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G et al (2017) Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 38(24):1883–1890
Vidan MT, Blaya-Novakova V, Sanchez E, Ortiz J, Serra-Rexach JA, Bueno H (2016) Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. Eur J Heart Fail 18(7):869–875
Turner G, Clegg A (2014) Best practice guidelines for the management of frailty: a British Geriatrics Society, Age UK and Royal College of General Practitioners report. Age Ageing 43(6):744–748
Brunner-La Rocca HP, Rickenbacher P, Muzzarelli S, Schindler R, Maeder MT, Jeker U et al (2012) End-of-life preferences of elderly patients with chronic heart failure. Eur Heart J 33(6):752–759
Lund LH, Benson L, Dahlström U, Edner M (2012) Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA 308(20):2108–2117
Lund LH, Benson L, Dahlström U, Edner M, Friberg L (2014) Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA 312(19):2008–2018
Rush CJ, Campbell RT, Jhund PS, Petrie MC, McMurray JJV (2018) Association is not causation: treatment effects cannot be estimated from observational data in heart failure. Eur Heart J 39(37):3417–3438
We greatly acknowledge the participation of heart failure nurses and cardiologists of all participating sites for including patients and entering patient data.
Servier, the Netherlands, funded the inclusion of data and software program. The steering committee (HBRLR, GL, AH, JB) received no funding for this project. This analysis was initiated by the authors and was designed, conducted, interpreted, and reported independently of the sponsor.
Conflict of interest
The authors declare no competing financial interest.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Linssen, G.C.M., Veenis, J.F., Kleberger, A. et al. Medical treatment of octogenarians with chronic heart failure: data from CHECK-HF. Clin Res Cardiol (2020). https://doi.org/10.1007/s00392-020-01607-y
- Heart failure
- Older people